Merck KGaA Signs Licensing Agreement with Abbisko for Pimicotinib

By Lalit Mishra

Pharma Deals Review: Vol 2023 Issue 12 (Table of Contents)

Published: 8 Dec-2023

DOI: 10.3833/pdr.v2023.i12.2842     ISSN: 1756-7874

Section: Licensing



In a significant move towards bolstering its oncology portfolio, Merck KGaA has entered into an exclusive license agreement with Abbisko Therapeutics for pimicotinib (ABSK021), a potent small molecule CSF-1R inhibitor currently in Phase III clinical trials for the treatment of tenosynovial giant cell tumour (TGCT)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details